Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
CJC-1295: Evidence Summary
Evidence summary for CJC-1295 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to CJC-1295 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| GH deficiency | Tier B | 5 | Phase II data as GHRH analog |
| Body composition | Tier C | 3 | Limited controlled data for body recomposition |
| Sleep quality | Tier D | 1 | Anecdotal and single small trial |